CY1126073T1 - Idhp για χρηση στην θεραπευτικη αναστολη σχηματισμου αιμοπεταλιων, στην θεραπευτικη υποκινηση αγγειογενεσης και στην αποτροπη ή θεραπεια αγγειακης ανοιας - Google Patents

Idhp για χρηση στην θεραπευτικη αναστολη σχηματισμου αιμοπεταλιων, στην θεραπευτικη υποκινηση αγγειογενεσης και στην αποτροπη ή θεραπεια αγγειακης ανοιας

Info

Publication number
CY1126073T1
CY1126073T1 CY20231100274T CY231100274T CY1126073T1 CY 1126073 T1 CY1126073 T1 CY 1126073T1 CY 20231100274 T CY20231100274 T CY 20231100274T CY 231100274 T CY231100274 T CY 231100274T CY 1126073 T1 CY1126073 T1 CY 1126073T1
Authority
CY
Cyprus
Prior art keywords
therapeutic
idhp
prevention
treatment
angiogenesis
Prior art date
Application number
CY20231100274T
Other languages
English (en)
Inventor
Xiaohui Zheng
Yajun BAI
Pu JIA
Yajun Zhang
Sha LIAO
Original Assignee
Northwest University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest University filed Critical Northwest University
Publication of CY1126073T1 publication Critical patent/CY1126073T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Χρήση β-(3,4-διυδροξυφαινυλ)-α-υδροξυπροπιονικού ισοπροπύλ εστέρα (IDHP) στην παρασκευή ενός φαρμάκου ή προϊόντος υγείας για αποτροπή και θεραπεία ασθενειών αθηροσκλήρωσης της στεφανιαίας. Ο IDHP μπορεί επίσης να χρησιμοποιηθεί για να παρεμποδίσει συσσωμάτωση αιμοπεταλίου, να υποκινήσει αγγειογένεση, και για να παρασκευάσει ένα φάρμακο και ένα προϊόν υγείας για αποτροπή και θεραπεία γεροντικής αγγειακής άνοιας.
CY20231100274T 2016-10-08 2023-06-13 Idhp για χρηση στην θεραπευτικη αναστολη σχηματισμου αιμοπεταλιων, στην θεραπευτικη υποκινηση αγγειογενεσης και στην αποτροπη ή θεραπεια αγγειακης ανοιας CY1126073T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610876752.3A CN106420688B (zh) 2016-10-08 2016-10-08 Idhp制备预防和治疗冠状动脉粥样硬化疾病药物的应用
PCT/CN2017/104278 WO2018064953A1 (zh) 2016-10-08 2017-09-29 Idhp在制备预防和治疗冠状动脉粥样硬化疾病药物或保健品中的应用

Publications (1)

Publication Number Publication Date
CY1126073T1 true CY1126073T1 (el) 2023-11-15

Family

ID=58172355

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100274T CY1126073T1 (el) 2016-10-08 2023-06-13 Idhp για χρηση στην θεραπευτικη αναστολη σχηματισμου αιμοπεταλιων, στην θεραπευτικη υποκινηση αγγειογενεσης και στην αποτροπη ή θεραπεια αγγειακης ανοιας

Country Status (16)

Country Link
US (1) US10993926B2 (el)
EP (1) EP3524241B1 (el)
JP (1) JP6851652B2 (el)
KR (1) KR102286297B1 (el)
CN (1) CN106420688B (el)
AU (1) AU2017340305B2 (el)
BR (1) BR112019006957A2 (el)
CA (1) CA3039287C (el)
CY (1) CY1126073T1 (el)
HU (1) HUE063053T2 (el)
IL (1) IL265753B2 (el)
MY (1) MY195760A (el)
PL (1) PL3524241T3 (el)
RU (1) RU2719391C1 (el)
SG (1) SG11201902987SA (el)
WO (1) WO2018064953A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420688B (zh) * 2016-10-08 2017-11-10 西北大学 Idhp制备预防和治疗冠状动脉粥样硬化疾病药物的应用
KR102529594B1 (ko) 2021-06-23 2023-05-09 재단법인 아산사회복지재단 대동맥판막 협착증 진단 및 예후 예측을 위한 바이오마커로서 항-시트룰린화 펩티드 항체의 용도
KR102643120B1 (ko) 2021-11-12 2024-03-05 재단법인 아산사회복지재단 대동맥판막 협착증의 진단을 위한 미토콘드리아 바이오마커 및 미토콘드리아 활성화제를 포함하는 대동맥판막 협착증의 예방 또는 치료용 약학적 조성물
KR20240020754A (ko) 2022-08-08 2024-02-16 재단법인 아산사회복지재단 Pad 저해제를 포함하는 퇴행성 판막 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035579A1 (en) * 1996-03-27 1997-10-02 Merck & Co., Inc. A method for inhibiting clot formation
KR20040044514A (ko) 2001-09-14 2004-05-28 미쯔비시 웰 파마 가부시키가이샤 항혈전약과 피라졸론 유도체의 조합 약제
JP3895228B2 (ja) * 2002-05-07 2007-03-22 松下電器産業株式会社 無線通信装置および到来方向推定方法
CN100441563C (zh) * 2004-06-03 2008-12-10 西安交通大学 β-（3，4-二羟基苯基）-α-羟基丙酸异丙酯及其合成方法
CN101596196A (zh) * 2008-06-02 2009-12-09 北京科士蓝医药技术有限公司 川芎嗪和丹参素的组合物及其药理活性研究
CN106420688B (zh) 2016-10-08 2017-11-10 西北大学 Idhp制备预防和治疗冠状动脉粥样硬化疾病药物的应用

Also Published As

Publication number Publication date
US10993926B2 (en) 2021-05-04
EP3524241B1 (en) 2023-06-07
JP2019537561A (ja) 2019-12-26
JP6851652B2 (ja) 2021-03-31
BR112019006957A2 (pt) 2019-07-02
CN106420688A (zh) 2017-02-22
PL3524241T3 (pl) 2023-07-17
WO2018064953A1 (zh) 2018-04-12
CA3039287A1 (en) 2018-04-12
NZ752717A (en) 2020-12-18
CA3039287C (en) 2021-02-16
US20200038357A1 (en) 2020-02-06
CN106420688B (zh) 2017-11-10
AU2017340305B2 (en) 2020-07-09
EP3524241A4 (en) 2020-05-27
EP3524241C0 (en) 2023-06-07
IL265753B2 (en) 2023-02-01
IL265753B (en) 2022-10-01
HUE063053T2 (hu) 2023-12-28
EP3524241A1 (en) 2019-08-14
KR102286297B1 (ko) 2021-08-09
IL265753A (en) 2019-06-30
SG11201902987SA (en) 2019-05-30
AU2017340305A1 (en) 2019-05-02
MY195760A (en) 2023-02-09
KR20190075953A (ko) 2019-07-01
RU2719391C1 (ru) 2020-04-17

Similar Documents

Publication Publication Date Title
CY1126073T1 (el) Idhp για χρηση στην θεραπευτικη αναστολη σχηματισμου αιμοπεταλιων, στην θεραπευτικη υποκινηση αγγειογενεσης και στην αποτροπη ή θεραπεια αγγειακης ανοιας
PH12016502256A1 (en) Medical use
MX2024010140A (es) Nuevos metodos.
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
JOP20210161A1 (ar) مشتقات أكسوبيريدين تحمل بدائل
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
TN2016000498A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1118532T1 (el) Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης
MX2016008968A (es) Compuestos organicos.
MX2021003651A (es) Formulacion que comprende aceite ozonizado en el tratamiento de un tumor.
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
EA201891647A1 (ru) Фармацевтическая композиция для профилактики и лечения нарушений сна
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease
TH168817A (th) อนุพันธ์อินโดลิซีนซึ่งเป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3-ไคเนส
TH168817B (th) อนุพันธ์อินโดลิซีนซึ่งเป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3-ไคเนส
TH165163A (th) สารประกอบซับสทิทิวเทดเททระไฮโดรคาร์บาโซล และคาร์บาโซลคาร์บอกแชมีด ที่ใช้ประโยชน์เป็นสารยับยั้บการทำหน้าที่ของไคเนส
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
TH170136B (th) อินดาโซลคาร์บอกซาไมด์แบบใหม่ กระบวนการในการเตรียมสารดังกล่าว ยาเตรียม ทางเภสัชกรรมซึ่งประกอบรวมด้วยสารดังกล่าว และการใช้สารดังกล่าว ในการผลิตยารักษาโรค
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
UA108139U (uk) Спосіб терапії корів з ендометритом, як профілактика гонадопатій
TH170298A (th) สารประกอบชนิดใหม่สำหรับการบำบัดโรคมะเร็ง